We are live on ! Find out more
GILD icon

Gilead Sciences

1,719 hedge funds and large institutions have $87.4B invested in Gilead Sciences in 2024 Q3 according to their latest regulatory filings, with 170 funds opening new positions, 629 increasing their positions, 698 reducing their positions, and 114 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more first-time investments, than exits

New positions opened: 170 | Existing positions closed: 114

36% more funds holding in top 10

Funds holding in top 10: 1419 (+5)

22% more capital invested

Capital invested by funds: $71.8B → $87.4B (+$15.6B)

2% more funds holding

Funds holding: 1,6791,719 (+40)

3% more call options, than puts

Call options by funds: $958M | Put options by funds: $928M

0.54% more ownership

Funds ownership: 83.31%83.86% (+0.54%)

10% less repeat investments, than reductions

Existing positions increased: 629 | Existing positions reduced: 698

Holders
1,719
Holders Change
+40
Holders Change %
+2.38%
% of All Funds
24.68%
Holding in Top 10
19
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+35.71%
% of All Funds
0.27%
New
170
Increased
629
Reduced
698
Closed
114
Calls
$958M
Puts
$928M
Net Calls
+$30M
Net Calls Change
-$261M
Name Holding Trade Value Shares
Change
Change in
Stake
FTWA
851
Fifth Third Wealth Advisors
Ohio
$1.08M +$104K +1,364 +12%
FIM
852
Fernwood Investment Management
Massachusetts
$1.07M -$141K -1,850 -13%
MIS
853
Morningstar Investment Services
Illinois
$1.07M -$72.5K -950 -7%
CI
854
Cigna Investments
Connecticut
$1.07M -$25.8K -338 -3%
IPW
855
Impact Partnership Wealth
Georgia
$1.07M -$15.1K -198 -2%
CGIM
856
Capital Group Investment Management
Singapore
$1.06M
MIP
857
Mondrian Investment Partners
United Kingdom
$1.06M +$37.7K +494 +4%
KFS
858
Keynote Financial Services
Connecticut
$1.05M +$10.8K +141 +1%
TAM
859
Todd Asset Management
Kentucky
$1.05M
BC
860
Belmont Capital
California
$1.04M -$832K -10,900 -47%
RCA
861
Ranch Capital Advisors
Florida
$1.04M +$68.4K +897 +8%
BFA
862
Benedict Financial Advisors
Georgia
$1.04M -$12.8K -168 -1%
FFS
863
Founders Financial Securities
Maryland
$1.03M +$2.98K +39 +0.3%
KCM
864
Kathmere Capital Management
Pennsylvania
$1.03M +$173K +2,266 +23%
CAG
865
Crestwood Advisors Group
Massachusetts
$1.02M +$85.2K +1,116 +10%
VHAM
866
Van Hulzen Asset Management
California
$1.02M +$992 +13 +0.1%
MWM
867
Mission Wealth Management
California
$1.01M -$31.5K -413 -3%
AWA
868
Alta Wealth Advisors
Massachusetts
$1.01M -$1.45K -19 -0.2%
DCM
869
Donaldson Capital Management
Indiana
$1.01M -$11.1K -145 -1%
SC
870
SouthState Corp
Florida
$1.01M -$197K -2,584 -18%
Capstone Investment Advisors
871
Capstone Investment Advisors
New York
$1.01M -$6.06M -79,408 -87%
OGC
872
Oak Grove Capital
New Hampshire
$1.01M +$107K +1,400 +13%
BJL
873
Brighton Jones LLC
Washington
$998K +$7.86K +103 +0.9%
QCG
874
Quadrant Capital Group
Ohio
$998K +$37.5K +491 +4%
AAM
875
Auxier Asset Management
Oregon
$987K -$3.66K -48 -0.4%

GILD Hedge Fund Activity: Q3 2024 in Review

1,719 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2024, worth a combined $87.4B — up 22% from $71.8B a quarter earlier.

Buyers outnumbered sellers: 170 funds opened new GILD positions and 114 closed out — a net gain of 56 holders — while 629 added to existing stakes and 698 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $1.12B. The largest seller was LM Advisors, exiting entirely with an estimated $550M sold.

  • 1,719 institutional investors held Gilead Sciences (GILD) as of Q3 2024, up from 1,679 in Q2 2024.
  • Funds reported $87.4B of Gilead Sciences stock for Q3 2024, up 22% quarter-over-quarter.
  • 170 funds opened new Gilead Sciences positions in Q3 2024 and 114 closed out, a net change of +56 holders.
  • The largest Gilead Sciences buyer in Q3 2024 was Fidelity Investments, an estimated $1.12B added.
  • The largest Gilead Sciences seller in Q3 2024 was LM Advisors, an estimated $550M sold.

Based on aggregated 13F filings for Q3 2024.